Overview

Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

Status:
Terminated

Trial end date:
2008-03-01

Target enrollment:

Participant gender:

Summary

Endothelin-1 is a powerful substance that may be involved in causing hemodynamic instability (problems related to unstable blood pressure) during and after open heart surgery. Tezosentan is an investigational intravenous drug that blocks the endothelin receptors. This clinical trial will assess the potential benefit of tezosentan compared with placebo in the treatment of patients undergoing open heart surgery with cardiopulmonary bypass (CPB). Treatment time is from the start of surgery up to 24 hours.

Phase:

Phase 3

Details

Lead Sponsor:

Actelion
Idorsia Pharmaceuticals Ltd.

Treatments:

Epoprostenol
Tezosentan